Related Experiment Videos
Comorbidity in patients with prostate cancer and its relevance to treatment choice
P N Post1, P J Kil, A J Hendrikx
1Comprehensive Cancer Centre South, Eindhoven, The Netherlands. p.post@ikz.nl
Insights
Comorbidity is common in prostate cancer patients, particularly older men. Treatment decisions for localized prostate cancer primarily depend on patient age and surgeon experience, not comorbidity.
Area of Science:
- Oncology
- Geriatric Medicine
- Public Health
Background:
- Comorbidity is increasingly recognized as a significant factor in cancer patient management.
- Understanding comorbidity prevalence is crucial for personalized prostate cancer treatment strategies.
Purpose of the Study:
- To determine the prevalence of comorbidity in prostate cancer patients.
- To investigate the relationship between comorbidity, patient characteristics, and treatment selection for localized prostate cancer.
Main Methods:
- Analysis of data from the Eindhoven Cancer Registry (1993-1996) for 2941 prostate cancer patients.
- Logistic regression modeling to identify factors influencing treatment choice.
Main Results:
- Comorbidity prevalence increased with age, reaching 53% in men over 75.
- Cardiovascular and chronic obstructive lung diseases were the most frequent comorbidities.
- Radical prostatectomy was more common in younger patients with localized, moderately differentiated tumors, influenced more by age and hospital caseload than comorbidity.
Conclusions:
- Comorbidity is prevalent in prostate cancer patients.
- Treatment decisions for localized prostate cancer in Southern Netherlands were primarily driven by patient age and urologist experience, with limited influence from comorbidity.
Objective:
To evaluate the prevalence of comorbidity among patients with prostate cancer in relation to tumour and patient characteristics and to assess if comorbidity was a determining factor in the treatment choice for patients with localized prostate cancer.
Patients And Methods:
Serious comorbidity was recorded in the Eindhoven Cancer Registry (according to a published list of such diseases) for all patients (2941) with prostate cancer newly diagnosed between 1993 and 1996 in the southern part of The Netherlands. Logistic regression was then used to assess which factors determined the treatment choice.
Results:
The prevalence of at least one serious comorbid condition was 38% for patients aged 60-69 years, 48% when aged 70-74 years and 53% for those aged >/=75 years, the cardiovascular and chronic obstructive lung diseases being most frequent. Patients aged 60-69 years were more likely to be treated with radical prostatectomy for moderately differentiated tumour confined to the prostate, or when younger and diagnosed in a hospital with a high case-load. The presence of comorbidity had little influence of this choice.
Conclusion:
Comorbidity was common in patients with prostate cancer, but the decision of urologists in the southern Netherlands to use radical prostatectomy was determined largely by the patient's age and the urologist's experience.